Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BiondVax Pharmaceuticals Ltd. - American Depositary Shares (NQ:BVXV)

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Sep 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about BiondVax Pharmaceuticals Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well Positioned to Move next NanoAb Candidates into Clinical Application
Via Investor Brand Network
Topics Intellectual Property
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Expands Offering to Include Boutique End-to-End CDMO Services
Via Investor Brand Network
Exploring the Link Between Hypertension, Asthma
Via Investor Brand Network
BioMedNewsBreaks – MoonLake Immunotherapeutics’ (NASDAQ: MLTX) Shares See Significant Increase Based on Success of Phase 2 Trial
Via Investor Brand Network
Why Women with MS See Decreased Symptoms When Pregnant
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Expands Focus with Development of New NanoAb Therapeutics
Via Investor Brand Network
Research Shows Autoimmune Ailments Rising
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 32 companies reached new 52-week lows. 
Via Benzinga
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Big Pharma Competencies to Bring Innovative Therapies to Market Quicker, at Lower Cost
Via Investor Brand Network
Transplant Medicine Plagued by Organ Shortages, Pandemic-Induced Challenges
Via Investor Brand Network
New Computational Platform to Broaden Options of Potential Immunotherapy Targets in Cancer Treatment
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Enters Development, Commercialization Agreement for Novel Anti-IL-17 Antibody
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 69 stocks hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding. 
Via Benzinga
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Displays CDMO Expertise at Prestigious Biomed Israel Conference
Via Investor Brand Network
Researchers ID Promising Strategy Against Immunotherapy Side Effects
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives Buy Rating and $70 Target Price; Releases Q1 2023 and Business Update
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Provides Business Update, Reports FY2022 Financial Results
Via Investor Brand Network
New Evidence Proves Link Between Glandular Fever Virus and MS
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Looking to Complement Core Focus with CDMO Offering
Via Investor Brand Network
African Researchers Collaborate to Gather Data on Infectious Illnesses
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q1 2023 Financial Results, Business Update
Via Investor Brand Network
BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update
Via ACCESSWIRE
Study Finds 10% of People in UK Have Autoimmune Disorders
Via Investor Brand Network
Researchers ID Antivirals That Can Fight New Infectious Illnesses
Via Investor Brand Network
Study Shows that Skin Conditions May Indicate Presence of Rheumatic Disease
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aims to Complement its NanoAb Core Focus with Comprehensive Contract Development 2and Manufacturing Organization Services
Via Investor Brand Network
Study Finds That Different Subtypes of Epilepsy Trigger Different Autoimmune Conditions
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.